Brief: Amylyx Pharmaceuticals Announces Positive Topline Results From Phase 2 Helios Clinical Trial Demonstrating Sustained Improvements With AMX0035 In People Living With Wolfram Syndrome

Amylyx Pharmaceuticals

17/10/2024 14:07

Oct 17 (Reuters) - Amylyx Pharmaceuticals Inc  AMLX.O :
    * AMYLYX PHARMACEUTICALS ANNOUNCES POSITIVE TOPLINE RESULTS
FROM
PHASE 2 HELIOS CLINICAL TRIAL DEMONSTRATING SUSTAINED
IMPROVEMENTS WITH AMX0035 IN PEOPLE LIVING WITH WOLFRAM SYNDROME
    * AMYLYX PHARMACEUTICALS INC - IMPROVEMENT IN PANCREATIC
FUNCTION
OBSERVED AFTER 24 WEEKS OF AMX0035
    * AMYLYX PHARMACEUTICALS INC - AMX0035 GENERALLY
WELL-TOLERATED IN
ALL PARTICIPANTS
    * AMYLYX PHARMACEUTICALS INC - TO MEET FDA FOR PHASE 3
PROGRAM,
UPDATE EXPECTED IN 2025
    * AMYLYX PHARMACEUTICALS : SAFETY PROFILE OF AMX0035 IN
HELIOS WAS
CONSISTENT WITH PRIOR SAFETY DATA & WAS GENERALLY WELL-TOLERATED

Source text for Eikon:  ID:nBwNnmC4a 
Further company coverage:  AMLX.O 

 ((Reuters.Briefs@thomsonreuters.com;))